BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
复制标题

DOI:
10.1016/j.ccell.2018.01.019
复制
发表时间:
2018-03-12
期刊:
影响因子:
50.3
通讯作者:
Mills GB
Mills GB
中科院分区:
医学1区
文献类型:
--
作者:
Sun C;Yin J;Fang Y;Chen J;Jeong KJ;Chen X;Vellano CP;Ju Z;Zhao W;Zhang D;Lu Y;Meric-Bernstam F;Yap TA;Hattersley M;O'Connor MJ;Chen H;Fawell S;Lin SY;Peng G;Mills GB

文献摘要

参考文献

被引文献

相似文献

聚(adp -核糖)聚合酶抑制剂(PARPi)在由BRCA1、BRCA2和其他途径成员突变引起的同源重组(HR)缺陷(HRD)细胞中具有选择性活性。我们寻找在HR敏感细胞中诱导HRD的小分子,以诱导PARPi的合成致死性并扩展PARPi的用途。我们证明,抑制含溴结构域4 (BRD4)可诱导HRD,并使多种肿瘤谱系的细胞对PARPi敏感,无论BRCA1/2、TP53、RAS或BRAF突变状态如何,通过耗尽DNA双支架断裂切除蛋白CtIP [c -末端结合蛋白(CtBP)相互作用蛋白]。重要的是,BRD4抑制剂(BRD4i)治疗逆转了PARPi耐药的多种机制。此外,PARPi和BRD4i在多种体内模型中具有协同作用。Sun等人的研究表明,BRD4的抑制通过减少CtBP在多种肿瘤类型的细胞中诱导同源重组缺陷,并使它们对PARP抑制敏感。因此,抑制BRD4逆转了对PARP抑制剂的耐药性,并扩大了PARP抑制剂的潜在用途。
Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1, BRCA2, and other pathway members. We sought small molecules that induce HRD in HR competent cells in order to induce synthetic lethality with PARPi and extend the utility of PARPi. We demonstrated that inhibition of bromodomain containing 4 (BRD4) induced HRD and sensitized cells across multiple tumor lineages to PARPi regardless of BRCA1/2, TP53, RAS, or BRAF mutation status through depletion of the DNA double stand break resection protein CtIP [C-terminal binding protein (CtBP) interacting protein]. Importantly, BRD4 inhibitor (BRD4i) treatment reversed multiple mechanisms of resistance to PARPi. Furthermore, PARPi and BRD4i are synergistic in multiple in vivo models. Sun et al. show that inhibition of BRD4 induces homologous recombination deficiency, through depletion of CtBP, in cells across multiple tumor types and sensitizes them to PARP inhibition. Thus, inhibition of BRD4 reverses resistance to PARP inhibitors and expands the potential use of PARP inhibitors.
选择性抑制BET溴结构域。
DOI: 10.1038/nature09504
发表时间: 2010-12-23
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1038/nature18325
发表时间: 2016-07-21
期刊: Nature
影响因子: 64.8
作者:
Ray Chaudhuri A;Callen E;Ding X;Gogola E;Duarte AA;Lee JE;Wong N;Lafarga V;Calvo JA;Panzarino NJ;John S;Day A;Crespo AV;Shen B;Starnes LM;de Ruiter JR;Daniel JA;Konstantinopoulos PA;Cortez D;Cantor SB;Fernandez-Capetillo O;Ge K;Jonkers J;Rottenberg S;Sharan SK;Nussenzweig A
通讯作者: Nussenzweig A
DOI: 10.1038/nsmb.2937
发表时间: 2015-02
影响因子: 16.8
作者:
Davies OR;Forment JV;Sun M;Belotserkovskaya R;Coates J;Galanty Y;Demir M;Morton CR;Rzechorzek NJ;Jackson SP;Pellegrini L
通讯作者: Pellegrini L
DOI: 10.1038/nsmb.1710
发表时间: 2010-01
影响因子: 16.8
作者:
通讯作者: --
人CTIP介导DNA终端切除和双链断裂修复的细胞周期控制。
DOI: 10.1074/jbc.m808906200
发表时间: 2009-04-03
期刊: The Journal of biological chemistry
影响因子: --
作者:
Huertas P;Jackson SP
通讯作者: Jackson SP